Last reviewed · How we verify
Corporacion Parc Tauli — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
1 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Hydrochlorothiazide and furosemide | Hydrochlorothiazide and furosemide | marketed | ||||
| Bupivacaine 7 mg | Bupivacaine 7 mg | marketed | ||||
| fentanyl 15 microg | fentanyl 15 microg | marketed | Opioid agonist | Mu-opioid receptor (OPRM1) | Pain Management | |
| L-BUPIVACAINE ; MORPHINE | L-BUPIVACAINE ; MORPHINE | phase 3 | Local anesthetic + opioid analgesic combination | Voltage-gated sodium channels (L-bupivacaine); mu-opioid receptor (morphine) | Anesthesia and Pain Management |
Therapeutic area mix
- Anesthesia and Pain Management · 1
- Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aga Khan University · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Beijing Friendship Hospital · 1 shared drug class
- Cephalon · 1 shared drug class
- Ciusss de L'Est de l'Île de Montréal · 1 shared drug class
- Conrad Arnfinn Bjørshol · 1 shared drug class
- Aarhus University Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Corporacion Parc Tauli:
- Corporacion Parc Tauli pipeline updates — RSS
- Corporacion Parc Tauli pipeline updates — Atom
- Corporacion Parc Tauli pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Corporacion Parc Tauli — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/corporacion-parc-tauli. Accessed 2026-05-16.